Doylestown, PA. 9/27/2010 – ALS Biopharma, LLC is pleased to announce a strategic alliance with Vybion, a platform biologics development company located in Ithaca, New York. Vybion will provide a license to ALS Biopharma for its patented PEGylation technology for the purpose of preparing novel biologic therapeutics for the treatment of ALS and related neuropathies. Vybion is currently producing modified biologic therapeutics for evaluation by ALS Biopharma. In addition, Lee Henderson, Ph.D., CEO of Vybion, has been appointed to serve on the Scientific Advisory Board of ALS Biopharma.
ALS Biopharma, LLC is an emerging discovery and development phase biopharmaceutical company focused on rapidly bringing a disease modifying biologic therapy to the clinic for the orphan indication of ALS. ALS Biopharma is located at the Pennsylvania Biotechnology Center, a Pennsylvania Keystone Innovation Zone in Bucks County, PA.